ArticleACS omega2026
pH-Responsive Apalutamide-Loaded ZIF‑8 Nanoparticles for Zinc-Enhanced Dual Cytotoxicity in Prostate Cancer.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apalutamide (APA) is a recently FDA-approved androgen receptor inhibitor for the treatment of nonmetastatic castration-resistant prostate cancer. Herein, we report a pH-responsive, dual-acting nanocarrier system based on zeolitic imidazolate framework-8 (ZIF-8) to enhance the therapeutic efficacy of APA. APA was successfully encapsulated into ZIF-8 nanoparticles with an encapsulation efficiency of 69.4% and a drug loading capacity of 47.8% (APA@ZIF-8). The structural and physicochemical properties of ZIF-8 and APA@ZIF-8 were comprehensively characterized using FTIR, SEM, STEM, DLS, EDX, PXRD, TGA, and BET analyses. Drug release studies demonstrated a pronounced pH-dependent behavior, with a faster release at pH 5.0 (93% over 120 h) compared to pH 7.4 (62% over 120 h), indicating suitability for the acidic tumor microenvironment. Biocompatibility assessments, including hemolysis and serum protein binding assays, confirmed the hemocompatible nature of both ZIF-8 and APA@ZIF-8 nanoparticles. The biological effects of APA, ZIF-8, and APA@ZIF-8 were evaluated through cell viability, cell cycle progression, reactive oxygen species generation, apoptosis, and androgen receptor transcriptional activity in prostate cancer and healthy cell lines. The results reveal that the pH-triggered biodegradation of ZIF-8 leads to zinc ion release, which, together with APA, contributes to enhanced cytotoxic effects in prostate cancer cells, highlighting the potential of APA@ZIF-8 as a zinc-enhanced dual cytotoxic nanotherapeutic platform.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.